Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
artificial, deadline, discrete, EMA, Goette, hand, human, Inspector, intelligence, judgment, met, modified, NESHAP, PID, Roland, satisfactory, Strength
Removed:
ACD, August, Blood, flat, immunohematology, injunction, lawsuit, permanent, preliminary, prepaid, revision, sterilizer, submitted, Vacutainer
Financial report summary
?Risks
- Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations.
- Our international operations subject us to certain business risks.
- The medical technology industry is very competitive.
- We are subject to foreign currency exchange risk.
- Market dynamics, changes in reimbursement practices and coverage policies and third-party payer cost containment measures could affect the demand for our products and the prices at which they are sold.
- Our future growth is dependent in part upon the development of new products, and there can be no assurance that such products will be developed.
- We are subject to risks associated with public health crises, such as pandemics and epidemics, including COVID-19, which could have a material adverse effect on our business. The nature and extent of future impacts are highly uncertain and unpredictable.
- Reductions in customers’ research budgets or government funding may adversely affect our business.
- We need to attract and retain key employees to be competitive.
- Breaches or breakdowns of our information and technology systems could have a material adverse effect on our operations.
- A reduction or interruption in the supply of certain raw materials and components could adversely affect our operating results.
- Interruption of our manufacturing or sterilization operations could adversely affect our business.
- Climate change, or legal, regulatory or market measures to address climate change, could adversely affect our business, financial condition or results of operations.
- We are subject to lawsuits.
- We are subject to extensive regulation.
- Defects or quality issues associated with our products could adversely affect the results of our operations.
- Our operations are dependent in part on patents and other intellectual property assets.
- We may not be able to service all of our indebtedness.
- The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses.
- Risks relating to spin-off of Embecta Corp.
- We cannot guarantee that any of our strategic acquisitions, investments or alliances will be successful.
- Natural disasters, war and other events beyond our control could disrupt our business and adversely affect our future revenues and operating income.
Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
- Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”).
- BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East and Africa (collectively referred to below as “EMA”), as well as Latin America and certain countries within Greater Asia.